Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report

Clinical Journal of Gastroenterology

Volumn 7, Issue 5, 2014, Pages 465-470

  Igawa, Takuro ^a,b   Fushimi, Soichiro ^b   Matsuo, Ryuichi ^a   Ikeda, Fusao ^b   Nouso, Kazuhiro ^b   Yoshino, Tadashi ^b   Nakatsukasa, Harushige ^a  

^a Mizushima Central Hospital   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Interferon free; Liver injury; Side effects; Simeprevir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALLOPURINOL; GLIMEPIRIDE; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; URSODEOXYCHOLIC ACID; VOGLIBOSE; ANTIVIRUS AGENT; INTERFERON;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPERURICEMIA; LIMIT OF DETECTION; LIVER BIOPSY; LIVER FUNCTION; LIVER INJURY; LYMPHOCYTE TRANSFORMATION TEST; MALAISE; MALE; TREATMENT RESPONSE; CLASSIFICATION; COMBINATION DRUG THERAPY; DRUG-INDUCED LIVER INJURY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; SEVERITY OF ILLNESS INDEX; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; SIMEPREVIR;

EID: 84919676066     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-014-0527-x     Document Type: Article

References (15)

1. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41:17–27.
2. Manns MP, McCone J, Davis MN, et al. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Intern. 2014;34:707–19.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J Med. 2011;364:2405–16.
4. Miller MH, Agarwal K, Austin A, et al. Review article: 2014 UK consensus guidelines—hepatitis C management and direct-acting anti-viral therapy. Alimentary Pharmacology Ther. 2014;39:1363–75.
5. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918–29.
6. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61(2):219–27.
7. Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941–53.
8. Report of SOVRIAD early post-marketing phase surveillance in Japan, in preparation.
9. Thurairajah PH, Thorburn D, Hubscher S, et al. Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007;25:1293–300.
10. Just-Nübling G, Korn S, Ludwig B, et al. Primary cytomegalovirus infection in an outpatient setting–laboratory markers and clinical aspects. Infection. 2003;31:318–23.
11. Takikawa H, Onji M, Takamori Y, et al. Proposal of diagnostic criteria for drug-induced liver injury revised by the DDW-J 2004 Workshop. Kanzo. 2005;46:85–90 (in Japanese).
12. Jay Lefkowitch H. Scheuer’s liver biopsy interpretation. 8th ed. Edinburgh: Elsevier Saunders; 2010.
13. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146:914–28.
14. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24(1):38–47.
15. Kraus I, Vitezic D. Acute hepatitis induced by alpha-interferon in a patient with chronic hepatitis C. Can J Gastroenterol. 2001;15(5):333–5.